One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Biohaven Pharmaceutical Holding Company Ltd. logo
Biohaven Pharmaceutical Holding Company Ltd. BHVN
$ 12.36 -9.65%
report update icon

Quarterly report 2022-Q2
added 06-06-2026

Biohaven Pharmaceutical Holding Company Ltd. Balance Sheet 2021-2011 | BHVN

Brief overview of Biohaven Pharmaceutical Holding Company Ltd.'s assets and capital

The comparison uses five available annual reports from the 2017–2021 interval.

Assets advanced +633.4% to $1.1 billion from $146.9 million; annual growth near 64.6% reflects a fast increase in scale.

Liability growth of +11,700.1% exceeded asset growth of +633.4%, increasing reliance on outside funding.

Equity was negative at the end of the period. Liabilities exceeded assets, leaving no balance sheet cushion.

Cash accounts for 16% of assets versus 89.5% initially. The change indicates the degree of financial flexibility.

The balance sheet carries negative retained earnings of -$2.6 billion. The figure may result from accumulated losses or an active capital return policy.

Overall picture

Biohaven Pharmaceutical Holding Company Ltd.'s balance sheet looks stretched: reliance on liabilities and a limited capital cushion increase sensitivity to weaker results.

Annual Balance Sheet Biohaven Pharmaceutical Holding Company Ltd.

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

455 M 136 M - -147 M - -23.1 M -1.46 M - - - -

Long Term Debt

627 M 267 M - 118 M - 595 K - - - - -

Long Term Debt Current

439 K 675 K - - - - - - - - -

Total Non Current Liabilities

- 802 M 286 M 120 M 5.49 M 1.9 M 476 K - - - -

Total Current Liabilities

534 M 278 M 66.2 M 19.5 M 9.43 M 7.94 M - - - - -

Total Liabilities

1.76 B 1.02 B 352 M 139 M 14.9 M 28.8 M 805 K - - - -

Retained Earnings

-2.59 B -1.74 B -972 M -444 M -203 M -75.5 M -11.8 M - - - -

Total Assets

1.08 B 687 M 344 M 290 M 147 M 27 M 1.89 M - - - -

Cash and Cash Equivalents

172 M 132 M 317 M 264 M 131 M 23.7 M 1.46 M - - - -

Book Value

-683 M -332 M -7.42 M 151 M 132 M -1.76 M 1.09 M - - - -

Total Shareholders Equity

-739 M -390 M -7.42 M 151 M 132 M -45 M 1.09 M - - - -

All numbers in USD currency

Quarterly Balance Sheet Biohaven Pharmaceutical Holding Company Ltd.

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - 765 M 634 M 627 M 619 M 274 M 271 M 267 M 264 M 1.36 M 267 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

- - 2.19 B 1.84 B 1.76 B 1.66 B 1.24 B 1.22 B 1.02 B 936 M 460 M 411 M 352 M 320 M 304 M 148 M 139 M 129 M 120 M 18.3 M 14.9 M 28.5 M 21.4 M 39.8 M 28.8 M 28.8 M 28.8 M 28.8 M - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- - -3.14 B -2.7 B -2.59 B -2.39 B -2.21 B -2 B -1.74 B -1.52 B -1.33 B -1.15 B -972 M -823 M -717 M -506 M -444 M -389 M -327 M -288 M -203 M -176 M -133 M -94.2 M -75.5 M -75.5 M -75.5 M -75.5 M - - - - - - - - - - - - - - - - - - - -

Total Assets

- - 1.39 B 1.37 B 1.08 B 1.13 B 846 M 1 B 687 M 782 M 424 M 533 M 344 M 439 M 491 M 245 M 290 M 195 M 239 M 126 M 147 M 185 M 214 M 60.2 M 27 M 27 M 27 M 27 M - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

- - 236 M 169 M 172 M 501 M 306 M 465 M 132 M 316 M 261 M 428 M 317 M 417 M 466 M 217 M 264 M 168 M 217 M 104 M 131 M 176 M 204 M 52.3 M 23.7 M 23.6 M 23.6 M 23.6 M 1.46 M - - - 1.77 M - - - - - - - - - - - - - - -

Book Value

- - -806 M -466 M -683 M -531 M -397 M -218 M -332 M -154 M -35.5 M 122 M -7.42 M 119 M 187 M 97 M 151 M 65.8 M 119 M 108 M 132 M 156 M 193 M 20.4 M -1.76 M -1.76 M -1.76 M -1.76 M - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

- - -801 M -462 M -739 M -588 M -454 M -276 M -390 M -212 M -35.5 M 122 M -7.42 M 119 M 187 M 97 M 151 M 65.8 M 119 M 108 M 132 M 156 M 193 M -53.5 M -45 M -45 M -45 M -45 M 1.09 M - - - 1.51 M - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Biohaven Pharmaceutical Holding Company Ltd., providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Galapagos NV Galapagos NV
GLPG
- - $ 1.83 B belgiumBelgium
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
$ 4.63 21.05 % $ 20 M israelIsrael
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 6.78 0.89 % $ 296 M usaUSA
Leap Therapeutics Leap Therapeutics
LPTX
- 368.57 % $ 41.9 M usaUSA
Lumos Pharma Lumos Pharma
LUMO
- - $ 35.3 M usaUSA
Gamida Cell Ltd. Gamida Cell Ltd.
GMDA
- -18.25 % $ 5.04 M israelIsrael
Axcella Health Axcella Health
AXLA
- -16.42 % $ 249 M usaUSA
Metacrine Metacrine
MTCR
- - $ 24.2 M usaUSA
Zealand Pharma A/S Zealand Pharma A/S
ZEAL
- 0.52 % $ 821 M danmarkDanmark
Myovant Sciences Ltd. Myovant Sciences Ltd.
MYOV
- -0.04 % $ 2.62 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Idera Pharmaceuticals Idera Pharmaceuticals
IDRA
- -23.04 % $ 26.6 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Verona Pharma plc Verona Pharma plc
VRNA
- - $ 69.7 B britainBritain
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Guardion Health Sciences Guardion Health Sciences
GHSI
- -0.31 % $ 3.64 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
- - $ 109 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
ImmunoGen ImmunoGen
IMGN
- - $ 7.92 B usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
- -8.77 % $ 12.4 M israelIsrael
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
Iterum Therapeutics Iterum Therapeutics
ITRM
- - $ 591 K irlandaIrlanda
Virpax Pharmaceuticals Virpax Pharmaceuticals
VRPX
- -45.12 % $ 2.85 M usaUSA
Navidea Biopharmaceuticals Navidea Biopharmaceuticals
NAVB
- -2.99 % $ 2.47 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
- - $ 23.9 M usaUSA
OncoSec Medical Incorporated OncoSec Medical Incorporated
ONCS
- 31.87 % $ 1.61 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Landos Biopharma Landos Biopharma
LABP
- 0.58 % $ 144 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
- - $ 35.4 M usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
- -5.16 % $ 5.39 M usaUSA
Sigilon Therapeutics Sigilon Therapeutics
SGTX
- - $ 728 M usaUSA
Regulus Therapeutics Regulus Therapeutics
RGLS
- - $ 155 M usaUSA
NGM Biopharmaceuticals NGM Biopharmaceuticals
NGM
- - $ 127 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Gilead Sciences Gilead Sciences
GILD
$ 166.01 -0.31 % $ 207 B usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
$ 22.14 -1.6 % $ 248 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
Turning Point Therapeutics Turning Point Therapeutics
TPTX
- -0.13 % $ 3.73 B usaUSA
Orgenesis Orgenesis
ORGS
- -33.86 % $ 61.2 M usaUSA
TCR2 Therapeutics TCR2 Therapeutics
TCRR
- - $ 58.1 M usaUSA
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited
ASLN
- -14.27 % $ 1.7 M singaporeSingapore